{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:57:43Z","timestamp":1790351863751,"version":"4.1.0"},"reference-count":155,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hematopoietic allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with hematological malignancies. However, due to disparities in major and minor histocompatibility antigens between donor and recipient, severe inflammatory complications can occur, among which chronic graft-versus-host disease (cGVHD) can be life-threatening. A classical therapeutic approach to the prevention and treatment of cGVHD has been broad immunosuppression, but more recently adjuvant immunotherapies have been tested. This review summarizes and discusses immunomodulatory approaches with T cells, including chimeric antigen receptor (CAR) and regulatory T cells, with natural killer (NK) cells and innate lymphoid cells (ILCs), and finally with mesenchymal stromal cells (MSC) and extracellular vesicles thereof. Clinical studies and pre-clinical research results are presented likewise.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1045168","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T10:41:47Z","timestamp":1668681707000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Matteo","family":"Doglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Crossland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Alho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Stary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o F.","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Eissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit","family":"Inngjerdingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European society for blood and marrow transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2040620720977039","DOI":"10.1177\/2040620720977039","article-title":"Adverse events in second-and third-line treatments for acute and chronic graft-versus-host disease: Systematic review","volume":"11","author":"Velickovic","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000951","article-title":"Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance","volume":"136","author":"Voermans","year":"2020","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nm915","article-title":"CD4+ CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation","volume":"9","author":"Edinger","year":"2003","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation","volume":"117","author":"Di Ianni","year":"2011","journal-title":"Blood J Am Soc Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI135754","article-title":"Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease","volume":"130","author":"Shrestha","year":"2020","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0000000000000499","article-title":"Innate lymphoid cells in treatment-induced gastrointestinal pathogenesis","volume":"14","author":"Omar","year":"2020","journal-title":"Curr Opin Supportive Palliative Care"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01217","article-title":"The graft-versus-leukemia effect in AML","volume":"9","author":"Sweeney","year":"2019","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129965","article-title":"Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease","volume":"130","author":"Divito","year":"2020","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2005.02.006","article-title":"T Cell immunity and graft-versus-host disease (GVHD)","volume":"5","author":"Ichiki","year":"2006","journal-title":"Autoimmun Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.578314","article-title":"New approaches for the treatment of chronic graft-versus-host disease: current status and future directions","volume":"11","author":"Saidu","year":"2020","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.357.6357.1250-r","article-title":"Tackling T cells in GVHD","volume":"357","author":"Pujanandez","year":"2017","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-752121","article-title":"Posttransplant chimeric antigen receptor therapy","volume":"131","author":"Smith","year":"2018","journal-title":"Blood J Am Soc Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e134939","DOI":"10.1172\/jci.insight.134939","article-title":"T Cell optimization for graft-versus-leukemia responses","volume":"5","author":"Biernacki","year":"2020","journal-title":"JCI Insight"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12433","article-title":"Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation","volume":"13","author":"Putnam","year":"2013","journal-title":"Am J Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol Therapy-Methods Clin Dev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell therapy: a new era in cancer immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"Curr Pharm Biotechnol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86827","article-title":"Driving allotolerance: CAR-expressing tregs for tolerance induction in organ and stem cell transplantation","volume":"126","author":"Edinger","year":"2016","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/biomedicines5040061","article-title":"The role of b cell targeting in chronic graft-versus-host disease","volume":"5","author":"Rhoades","year":"2017","journal-title":"Biomedicines"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2019.03.003","article-title":"B cells in chronic graft-versus-host disease","volume":"80","author":"McManigle","year":"2019","journal-title":"Hum Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-784017","article-title":"B-cell targeting in chronic graft-versus-host disease","volume":"131","author":"Zeiser","year":"2018","journal-title":"Blood J Am Soc Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Trans Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1006\/clim.1998.4666","article-title":"Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation","volume":"91","author":"Quaranta","year":"1999","journal-title":"Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2005.12.011","article-title":"The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery","volume":"34","author":"Patriarca","year":"2006","journal-title":"Exp Hematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-364414","article-title":"Donor b-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans","volume":"119","author":"Srinivasan","year":"2012","journal-title":"Blood J Am Soc Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood J Am Soc Hematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-758854","article-title":"Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-\u03b2 production","volume":"129","author":"Du","year":"2017","journal-title":"Blood J Am Soc Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.02.001","article-title":"Co-Activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model","volume":"41","author":"Ono","year":"2019","journal-title":"EBioMedicine"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41590-018-0289-6","article-title":"Thymic regulatory T cells arise via two distinct developmental programs","volume":"20","author":"Owen","year":"2019","journal-title":"Nat Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nature10434","article-title":"Peripheral education of the immune system by colonic commensal microbiota","volume":"478","author":"Lathrop","year":"2011","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.omtm.2018.01.006","article-title":"A rapamycin-based GMP-compatible process for the isolation and expansion of regulatory T cells for clinical trials","volume":"8","author":"Fraser","year":"2018","journal-title":"Mol Therapy-Methods Clin Dev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00211","article-title":"Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity","volume":"3","author":"Barzaghi","year":"2012","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-Host disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1257","article-title":"Reduced frequency of FOXP3+ CD4+ CD25+ regulatory T cells in patients with chronic graft-versus-host disease","volume":"106","author":"Zorn","year":"2005","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI41072","article-title":"Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation","volume":"120","author":"Matsuoka","year":"2010","journal-title":"J Clin Invest"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-672345","article-title":"Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD","volume":"127","author":"Alho","year":"2016","journal-title":"Blood J Am Soc Hematol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3389\/fimmu.2019.00334","article-title":"Naive and stem cell memory T cell subset recovery reveals opposing reconstitution patterns in CD4 and CD8 T cells in chronic graft vs","volume":"10","author":"Soares","year":"2019","journal-title":"Host disease Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2073","article-title":"Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+ CD25high regulatory T cells","volume":"103","author":"Clark","year":"2004","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"New Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-702852","article-title":"Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease","volume":"128","author":"Koreth","year":"2016","journal-title":"Blood J Am Soc Hematol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.smim.2006.01.006","article-title":"Clinical application of expanded CD4+ 25+ cells","volume":"18","author":"June","year":"2006","journal-title":"Semin Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2003.50027","article-title":"Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD4+ 25+ T cells to allow an effective graft-versus-leukemia response","volume":"9","author":"Jones","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nri2138","article-title":"Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans","volume":"7","author":"Roncarolo","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001809","article-title":"Massive ex vivo expansion of human natural regulatory T cells (Tregs) with minimal loss of in vivo functional activity","volume":"3","author":"Hippen","year":"2011","journal-title":"Sci Trans Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00375","article-title":"Large-Scale generation of human allospecific induced tregs with functional stability for use in immunotherapy in transplantation","volume":"11","author":"Alvarez-Salazar","year":"2020","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/sj.mt.6300341","article-title":"Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3","volume":"16","author":"Allan","year":"2008","journal-title":"Mol Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200838904","article-title":"Loss of FOXP3 expression in natural human CD4+ CD25+ regulatory T cells upon repetitive in vitro stimulation","volume":"39","author":"Hoffmann","year":"2009","journal-title":"Eur J Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-564401","article-title":"HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse","volume":"124","author":"Martelli","year":"2014","journal-title":"Blood J Am Soc Hematol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0618-x","article-title":"The \u201cultimate\u201d haploidentical transplantation for the elderly with high-risk acute myeloid leukemia","volume":"54","author":"Pierini","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood J Am Soc Hematol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-653667","article-title":"Umbilical cord blood\u2013derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect","volume":"127","author":"Brunstein","year":"2016","journal-title":"Blood J Am Soc Hematol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"35611","DOI":"10.18632\/oncotarget.26242","article-title":"Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution","volume":"9","author":"Kellner","year":"2018","journal-title":"Oncotarget"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e127244","DOI":"10.1172\/jci.insight.127244","article-title":"Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients","volume":"4","author":"Meyer","year":"2019","journal-title":"JCI Insight"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003739","article-title":"Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia","volume":"5","author":"Pierini","year":"2021","journal-title":"Blood Adv"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+ CD25+ CD127\u2013 T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2014.11.005","article-title":"Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease","volume":"17","author":"Theil","year":"2015","journal-title":"Cytotherapy"},{"key":"B63","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1182\/blood.V128.22.385.385","article-title":"A phase I study of donor regulatory T cells as treatment for steroid dependent\/refractory chronic graft versus host disease","volume":"128","author":"Johnston","year":"2016","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/bloodadvances.2021006625","article-title":"Phase I trial of regulatory T-cell donor lymphocyte infusion plus daily low-dose interleukin-2 for steroid-refractory chronic graft-versus-host disease","volume":"130","author":"Nikiforow","year":"2017","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-6367(21)00364-X","volume-title":"Continuous alloreactive T cell depletion and regulatory T cell expansion for the treatment of steroid-refractory or dependent chronic gvhd-a multicentre phase II clinical trial (CARE trial)","author":"Ahmad","year":"2021"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-044529","article-title":"In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation","volume":"109","author":"Nguyen","year":"2007","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/cei.13297","article-title":"Methods to manufacture regulatory T cells for cell therapy","volume":"197","author":"MacDonald","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/blood-2004-01-0086","article-title":"Large-Scale in vitro expansion of polyclonal human CD4+ CD25high regulatory T cells","volume":"104","author":"Hoffmann","year":"2004","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-603449","article-title":"Ex vivo fucosylation of third-party human regulatory T cells enhances anti\u2013graft-versus-host disease potency in vivo","volume":"125","author":"Parmar","year":"2015","journal-title":"Blood J Am Soc Hematol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e92865","DOI":"10.1172\/jci.insight.92865","article-title":"T Cells expressing chimeric antigen receptor promote immune tolerance","volume":"2","author":"Pierini","year":"2017","journal-title":"JCI Insight"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e136185","DOI":"10.1172\/jci.insight.136185","article-title":"CD19-targeted CAR regulatory T cells suppress b cell pathology without GvHD","volume":"5","author":"Imura","year":"2020","journal-title":"JCI Insight"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.864748","article-title":"Cytolytic CD4+ and CD8+ regulatory T-cells and implications for developing immunotherapies to combat graft-versus-host disease","volume":"13","author":"Bolivar-Wagers","year":"2022","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e126194","DOI":"10.1172\/jci.insight.126194","article-title":"Chimeric antigen receptor costimulation domains modulate human regulatory T cell function","volume":"5","author":"Boroughs","year":"2019","journal-title":"JCI Insight"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.02.006","article-title":"Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology","volume":"90","author":"Koristka","year":"2018","journal-title":"J Autoimmun"},{"key":"B76","doi-asserted-by":"publisher","first-page":"eaaz3866","DOI":"10.1126\/scitranslmed.aaz3866","article-title":"Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells","volume":"12","author":"Dawson","year":"2020","journal-title":"Sci Trans Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e160674","DOI":"10.1172\/jci.insight.160674","article-title":"Murine CAR19 tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responses","volume":"7","author":"Bolivar-Wagers","year":"2022","journal-title":"JCI Insight"},{"key":"B78","first-page":"86","article-title":"Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease","volume":"90","author":"Abrahamsen","year":"2005","journal-title":"Haematologica"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12483724","article-title":"Identification of natural killer (NK) cells in lesions of human cutaneous graft-versus-host disease: expression of a novel NK-associated surface antigen (Kp43) in mononuclear infiltrates","volume":"97","author":"Acevedo","year":"1991","journal-title":"J Invest Dermatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017014464","article-title":"Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD","volume":"2","author":"Bejanyan","year":"2018","journal-title":"Blood Adv"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(01)00275-0","article-title":"NK cells recover early and mediate cytotoxicity via perforin\/granzyme and Fas\/FasL pathways in umbilical cord blood recipients","volume":"62","author":"Brahmi","year":"2001","journal-title":"Hum Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.5.1937","article-title":"The role of transforming growth factor beta in the generation of suppression: an interaction between CD8+ T and NK cells","volume":"180","author":"Gray","year":"1994","journal-title":"J Exp Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217430","article-title":"MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-versus-host disease","volume":"114","author":"Boukouaci","year":"2009","journal-title":"Blood J Am Soc Hematol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2013.08.281","article-title":"Soluble MICA-NKG2D interaction upregulates IFN-\u03b3 production by activated CD3\u2013 CD56+ NK cells: Potential impact on chronic graft versus host disease","volume":"74","author":"Boukouaci","year":"2013","journal-title":"Hum Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.3.2211","article-title":"Excessive production of IFN-\u03b3 in patients with systemic lupus erythematosus and its contribution to induction of b lymphocyte stimulator\/B cell-activating factor\/TNF ligand superfamily-13B","volume":"181","author":"Harigai","year":"2008","journal-title":"J Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0114","article-title":"Targeting CD20+ aggressive b-cell non\u2013Hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice","volume":"3","author":"Chu","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0383-3","article-title":"Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells","volume":"57","author":"M\u00fcller","year":"2008","journal-title":"Cancer Immunol Immunotherapy"},{"key":"B89","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","article-title":"The biology of NKT cells","volume":"25","author":"Bendelac","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/372691a0","article-title":"Recognition of a lipid antigen by CD1-restricted \u03b1\u03b2+ T cells","volume":"372","author":"Beckman","year":"1994","journal-title":"Nature"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-0037-5","article-title":"Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation","volume":"85","author":"Vela-Ojeda","year":"2006","journal-title":"Ann Hematol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-165506","article-title":"Host natural killer T cells induce an interleukin-4\u2013dependent expansion of donor CD4+ CD25+ Foxp3+ T regulatory cells that protects against graft-versus-host disease","volume":"113","author":"Pillai","year":"2009","journal-title":"Blood J Am Soc Hematol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-752444","article-title":"Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells","volume":"129","author":"Du","year":"2017","journal-title":"Blood J Am Soc Hematol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.imlet.2006.05.001","article-title":"Modulation of acute graft-versus-host disease and chimerism after adoptive transfer of in vitro-expanded invariant V\u03b114 natural killer T cells","volume":"106","author":"Kuwatani","year":"2006","journal-title":"Immunol Lett"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-427781","article-title":"Human innate lymphoid cells","volume":"124","author":"Hazenberg","year":"2014","journal-title":"Blood J Am Soc Hematol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.07.017","article-title":"Innate lymphoid cells: 10 years on","volume":"174","author":"Vivier","year":"2018","journal-title":"Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.02.010","article-title":"Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12-and IL-15-responsive IFN-\u03b3-producing cells","volume":"38","author":"Fuchs","year":"2013","journal-title":"Immunity"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2131","article-title":"Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus","volume":"12","author":"Monticelli","year":"2011","journal-title":"Nat Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.08.002","article-title":"Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora","volume":"39","author":"Qiu","year":"2013","journal-title":"Immunity"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2659","article-title":"Restricting T cell responses","volume":"14","author":"Visan","year":"2013","journal-title":"Nat Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcle.2018.11.008","article-title":"Graft-versus-host disease","volume":"152","author":"Moreno","year":"2019","journal-title":"Medicina Cl\u00ednica (English Edition)"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.05.028","article-title":"Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease","volume":"37","author":"Hanash","year":"2012","journal-title":"Immunity"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91816","article-title":"Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease","volume":"127","author":"Bruce","year":"2017","journal-title":"J Clin Invest"},{"key":"B104","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood.V124.21.812.812","article-title":"Early disease relapse after tyrosine kinase inhibitor treatment discontinuation in CML is related both to low number and impaired function of NK-cells","volume":"124","author":"Ilander","year":"2014","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","first-page":"20406207211058333","DOI":"10.1177\/20406207211058333","article-title":"Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study","volume":"12","author":"Spindelboeck","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000176","article-title":"Human ectoenzyme-expressing ILC3: immunosuppressive innate cells that are depleted in graft-versus-host disease","volume":"3","author":"Hazenberg","year":"2019","journal-title":"Blood Adv"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2021.10.011","article-title":"Presence of innate lymphoid cells in allogeneic hematopoietic grafts correlates with reduced graft-versus-host disease","volume":"24","author":"Kroeze","year":"2022","journal-title":"Cytotherapy"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01076","article-title":"Immunosuppressive property of MSCs mediated by cell surface receptors","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.237","article-title":"Stromal cells\u2013are they really useful for GVHD","volume":"49","author":"Kaipe","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.609063","article-title":"Tolerance to bone marrow transplantation: do mesenchymal stromal cells still have a future for acute or chronic GvHD","volume":"11","author":"Introna","year":"2020","journal-title":"Front Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/17474086.2021.1860001","article-title":"Biomarkers for acute and chronic graft versus host disease: state of the art","volume":"14","author":"Giaccone","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.676756","article-title":"Von Willebrand factor, factor VIII, and other acute phase reactants as biomarkers of inflammation and endothelial dysfunction in chronic graft-Versus-Host disease","volume":"12","author":"Lelas","year":"2021","journal-title":"Front Immunol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-020-01592-z","article-title":"Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease\u2013a meta-analysis","volume":"11","author":"Morata-Tarifa","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.07.028","article-title":"Haploidentical transplantation with post-transplant cyclophosphamide versus unrelated donor hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"25","author":"Arcuri","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood J Am Soc Hematol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.373","article-title":"Prophylaxis regimens for GVHD: Systematic review and meta-analysis","volume":"43","author":"Ram","year":"2009","journal-title":"Bone marrow Transplant"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.761616","article-title":"Mesenchymal stromal cells for the treatment of graft versus host disease","volume":"12","author":"Kelly","year":"2021","journal-title":"Front Immunol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-022-02751-0","article-title":"Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review","volume":"13","author":"Li","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.195","article-title":"Mesenchymal stem cell as salvage treatment for refractory chronic GVHD","volume":"45","author":"Weng","year":"2010","journal-title":"Bone marrow Transplant"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-021-02304-x","article-title":"Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"12","author":"Li","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-019-1287-9","article-title":"The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease","volume":"10","author":"Zhao","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.20-0099","article-title":"Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: a phase II study","volume":"9","author":"Boberg","year":"2020","journal-title":"Stem Cells Trans Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.225","article-title":"Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory b cells producing interleukin 10","volume":"29","author":"Peng","year":"2015","journal-title":"Leukemia"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08907-9","article-title":"Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease","volume":"359","author":"Biedermann","year":"2002","journal-title":"Lancet"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2008.02.002","article-title":"Vascular endothelium as \u2018novel\u2019target of graft-versus-host disease","volume":"21","author":"Tichelli","year":"2008","journal-title":"Best Pract Res Clin haematology"},{"key":"B127","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.162.12.7022","article-title":"Human vascular endothelial cells favor clonal expansion of unusual alloreactive CTL","volume":"162","author":"Biedermann","year":"1999","journal-title":"J Immunol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/blood.V118.21.4693.4693","article-title":"Regulatory T cells enhance the allogeneic activity of endothelial-specific cytotoxic T lymphocytes\u2013protective effect of defibrotide","volume":"118","author":"Eissner","year":"2011","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12459","article-title":"Mesenchymal stromal cells protect endothelial cells from cytotoxic T lymphocyte-induced lysis","volume":"84","author":"Cahill","year":"2016","journal-title":"Scandinavian J Immunol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.regen.2018.01.001","article-title":"Dual IFN-\u03b3\/hypoxia priming enhances immunosuppression of mesenchymal stromal cells through regulatory proteins and metabolic mechanisms","volume":"1","author":"Wobma","year":"2018","journal-title":"J Immunol Regenerative Med"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-020-01659-x","article-title":"GVHD-derived plasma as a priming strategy of mesenchymal stem cells","volume":"11","author":"Silva-Carvalho","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0151-8","article-title":"Small hypoxia-primed mesenchymal stem cells attenuate graft-versus-host disease","volume":"32","author":"Kim","year":"2018","journal-title":"Leukemia"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8211","article-title":"Mesenchymal stem cells induce functionally active T-regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis","volume":"53","author":"Tasso","year":"2012","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2759","article-title":"Graft-versus-host disease amelioration by human bone marrow mesenchymal stromal\/stem cell-derived extracellular vesicles is associated with peripheral preservation of naive T cell populations","volume":"36","author":"Fujii","year":"2018","journal-title":"Stem Cells"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00556","article-title":"Immunomodulatory potential of human adipose mesenchymal stem cells derived exosomes on in vitro stimulated T cells","volume":"5","author":"Blazquez","year":"2014","journal-title":"Front Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008070798","article-title":"Mesenchymal stem cell-derived microvesicles protect against acute tubular injury","volume":"20","author":"Bruno","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037036","article-title":"Circulating mesenchymal stem cells microparticles in patients with cerebrovascular disease","volume":"7","author":"Kim","year":"2012","journal-title":"PloS One"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2009.12.021","article-title":"Derivation and characterization of human fetal MSCs: an alternative cell source for large-scale production of cardioprotective microparticles","volume":"48","author":"Lai","year":"2010","journal-title":"J Mol Cell Cardiol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2015.09.019","article-title":"ExoCarta: a web-based compendium of exosomal cargo","volume":"428","author":"Keerthikumar","year":"2016","journal-title":"J Mol Biol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2015.03.001","article-title":"Mesenchymal stem cell exosomes","volume":"40","author":"Lai","year":"2015","journal-title":"Semin Cell Dev Biol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"30087","DOI":"10.3402\/jev.v4.30087","article-title":"Applying extracellular vesicles based therapeutics in clinical trials\u2013an ISEV position paper","volume":"4","author":"Lener","year":"2015","journal-title":"J Extracellular Vesicles"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0534-8","article-title":"The crosstalk between autophagic and endo-\/exosomal pathways in antigen processing for MHC presentation in anticancer T cell immune responses","volume":"10","author":"You","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.41","article-title":"MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease","volume":"28","author":"Kordelas","year":"2014","journal-title":"Leukemia"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3390\/ijms18071450","article-title":"Mesenchymal stem\/stromal cell-derived extracellular vesicles and their potential as novel immunomodulatory therapeutic agents","volume":"18","author":"B\u00f6rger","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0680-7","article-title":"A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD","volume":"11","author":"Lai","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2018.02.372","article-title":"Mesenchymal stromal cell exosome\u2013enhanced regulatory T-cell production through an antigen-presenting cell\u2013mediated pathway","volume":"20","author":"Zhang","year":"2018","journal-title":"Cytotherapy"},{"key":"B147","doi-asserted-by":"publisher","first-page":"84","DOI":"10.21037\/sci.2017.09.06","article-title":"Clinical potential of mesenchymal stem\/stromal cell-derived extracellular vesicles","volume":"4","author":"Giebel","year":"2017","journal-title":"Stem Cell Invest"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines","volume":"7","author":"Th\u00e9ry","year":"2018","journal-title":"J Extracellular Vesicles"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2013.0479","article-title":"Mesenchymal stem cells secrete immunologically active exosomes","volume":"23","author":"Zhang","year":"2014","journal-title":"Stem Cells Dev"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.2217\/rme.11.35","article-title":"Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease","volume":"6","author":"Lai","year":"2011","journal-title":"Regenerative Med"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2009.12.003","article-title":"Exosome secreted by MSC reduces myocardial ischemia\/reperfusion injury","volume":"4","author":"Lai","year":"2010","journal-title":"Stem Cell Res"},{"key":"B152","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/jcmm.17114","article-title":"Human placental mesenchymal stromal cell-derived exosome-enriched extracellular vesicles for chronic cutaneous graft-versus-host disease: A case report","volume":"26","author":"Norooznezhad","year":"2022","journal-title":"J Cell Mol Med"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2016.0107","article-title":"Extracellular vesicles released from human umbilical cord-derived mesenchymal stromal cells prevent life-threatening acute graft-versus-host disease in a mouse model of allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Wang","year":"2016","journal-title":"Stem Cells Dev"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.17-0055","article-title":"Concise review: developing best-practice models for the therapeutic use of extracellular vesicles","volume":"6","author":"Reiner","year":"2017","journal-title":"Stem Cells Trans Med"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1609206","DOI":"10.1080\/20013078.2019.1609206","article-title":"Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications","volume":"8","author":"Witwer","year":"2019","journal-title":"J Extracellular Vesicles"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1045168\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T22:18:05Z","timestamp":1678659485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1045168\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":155,"alternative-id":["10.3389\/fimmu.2022.1045168"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1045168","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"article-number":"1045168"}}